SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Expect to report safety and early efficacy data from the Phase 1 dose-escalation study of ALX2004 in EGFR-expressing solid tumors and plan to host a KOL webinar to review the results in December 2026Topline data from 120 patients in Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in co…

ALXO

Related stories